Intracellular restriction factors in mammalian cells - An ancient defense system finds a modern foe

Current HIV Research

Volumn 4, Issue 2, 2006, Pages 141-168

  Baumann, Jörg G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

APOBEC; Fv 1; HIV; Lentiviruses; Restriction; Retroviruses; Trim5; Vif

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHILIN A; VIF PROTEIN; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CORRELATION ANALYSIS; DEFENSE MECHANISM; HEPATITIS B VIRUS; HUMAN; INNATE IMMUNITY; INTRACELLULAR SPACE; MAMMAL CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; VIRION; VIRUS CELL INTERACTION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; CARRIER PROTEINS; GENE PRODUCTS, VIF; HUMANS; IMMUNITY, NATURAL; NUCLEOSIDE DEAMINASES; PROTEINS; REPRESSOR PROTEINS; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; VIRUS REPLICATION;

EID: 33646166525     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016206776055093     Document Type: Review

References (407)

1. Aagaard L, Mikkelsen JG, Warming S, Duch M, Pedersen FS. (2002). Fv1-like restriction of N-tropic replication-competent murine leukaemia viruses in mCAT-1-expressing human cells. Journal of General Virology. 83: 439-442.
2. Adamson AL, Kenney S. (2001). Epstein-barr virus immediate-early protein BZLF1 is SUMO-1 modified and disrupts promyelocytic leukemia bodies. Journal of Virology. 75: 2388-2399.
3. Akari H, Fujita M, Kao S, Khan MA, Shehu-Xhilaga M, Adachi A, Strebel K. (2004). High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. Journal of Biological Chemistry. 279: 12355-12362.
4. Alce TM, Popik W. (2004). APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. Journal of Biological Chemistry. 279: 34083-34086.
5. Aldovini A, Young RA. (1990). Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. Journal of Virology. 64: 1920-1926.
6. Alexander WS, Hilton DJ. (2004). The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annual Review of Immunology. 22: 503-529.
7. Ali SH, Kasper JS, Arai T, DeCaprio JA. (2004). Cu17/p185/p 193 binding to simian virus 40 large T antigen has a role in cellular transformation. Journal of Virology. 78: 2749-2757.
8. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, Alobwede I, Trono D, Vlahov D, Donfield S, Goedert JJ, Phair J, Buchbinder S, O'Brien SJ, Telenti A, Winkler CA. (2004). APOBEC3G genetic variants and their influence on the progression to AIDS. Journal of Virology. 78: 11070-11076.
9. Anant S, Mukhopadhyay D, Sankaranand V, Kennedy S, Henderson JO, Davidson NO. (2001). ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. American Journal of Physiology - Cell Physiology. 281: C1904-C1916.
10. Arber W. (1965). Host-controlled modification of bacteriophage. Annual Review of Microbiology. 19: 365-378.
11. Auerbach MR, Shu C, Kaplan A, Singh IR. (2003). Functional characterization of a portion of the Moloney murine leukemia virus gag gene by genetic footprinting. Proceedings of the National Academy of Sciences of the USA. 100: 11678-11683.
12. Avela K, Lipsanen-Nyman M, Idanheimo N, Seemanova E, Rosengren S, Makela TP, Perheentupa J, Chapelle AD, Lehesjoki AE. (2000). Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism. Nature Genetics. 25: 298-301.
13. Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, Marx PA, Hahn BH, Sharp PM. (2003). Hybrid origin of SIV in chimpanzees. Science. 300: 1713.
14. Balint I, Muller A, Nagy A, Kovacs G. (2004). Cloning and characterisation of the RBCC728/TRIM36 zinc-binding protein from the tumor suppressor gene region at chromosome 5q22.3. Gene. 332: 45-50.
15. Bannert N, Kurth R. (2004). Retroelements and the human genome. new perspectives on an old relation. Proceedings of the National Academy of Sciences of the USA. 101 Suppl 2: 14572-14579.
16. Baraz L, Kotler M. (2004). The Vif protein of human immunodeficiency virus type 1 (HIV-1): enigmas and solutions. Current Medicinal Chemistry. 11: 221-231.
17. Bass BL. (1997). RNA editing and hypermutation by adenosine deamination. Trends in Biochemical Sciences. 22: 157-162.
18. Bassin RH, Duran-Troise G, Gerwin BI, Rein A. (1978). Abrogation of Fv-1b restriction with murine leukemia viruses inactivated by heat or by gamma irradiation. Journal of Virology. 26: 306-315.
19. Baumann JG, Unutmaz D, Miller MD, Breun SKJ, Grill SM, Mirro J, Littman DR, Rein A, KewalRamani VN. (2004). Murine T cells potently restrict human immunodeficiency virus infection. Journal of Virology. 78: 12537-12547.
20. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. (2004). Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. Journal of Molecular Biology. 337: 585-596.
21. Benit L, De Parseval N, Casella JF, Callebaut I, Cordonnier A, Heidmann T. (1997). Cloning of a new murine endogenous retrovirus, MuERV-L, with strong similarity to the human HERVL element and with a gag coding sequence closely related to the Fv1 restriction gene. Journal of Virology. 71: 5652-5657.
22. Berkhout B, Grigoriev A, Bakker M, Lukashov VV. (2002). Codon and amino acid usage in retroviral genomes is consistent with virus-specific nucleotide pressure. AIDS Research and Human Retroviruses. 18: 133-141.
23. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, Luban J. (2003). As(2)O(3) enhances retroviral reverse transcription and counteracts Refl antiviral activity. Journal of Virology. 77: 3167-3180.
24. Berthoux L, Sebastian S, Sokolskaja E, Luban J. (2004). Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. Journal of Virology. 78: 11739-11750.
25. Berthoux L, Sebastian S, Sayah DM, Luban J. (2005). Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologues. Journal of Virology. 79: 7883-7888.
26. Berthoux L, Sebastian S, Sokolskaja E, Luban J. (2005). Cyclophilin A is required for TRIM5{(alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proceedings of the National Academy of Sciences of the USA. 102: 14849-14853.
27. Besnier C, Takeuchi Y, Towers G. (2002). Restriction of lentivirus in monkeys. Proceedings of the National Academy of Sciences of the USA. 99: 11920-11925.
28. Besnier C, Ylinen L, Strange B, Lister A, Takeuchi Y, Goff SP, Towers GJ. (2003). Characterization of murine leukemia virus restriction in mammals. Journal of Virology. 77: 13403-13406.
29. Best S, Le Tissier P, Towers G, Stoye JP. (1996). Positional cloning of the mouse retrovirus restriction gene Fv1. Nature. 382: 826-829.
30. Bhagwat AS. (2004). DNA-cytosine deaminases: from antibody maturation to antiviral defense. DNA Repair (Amst). 3: 85-89.
31. Bibollet-Ruche F, Galat-Luong A, Cuny G, Sarni-Manchado P, Galat G, Durand JP, Pourrut X, Veas F. (1996). Simian immunodeficiency virus infection in a patas monkey (Erythrocebus patas): evidence for cross-species transmission from African green monkeys (Cercopithecus aethiops sabaeus) in the wild. Journal of General Virology. 77 (Pt 4): 773-781.
32. Bibollet-Ruche F, Bailes E, Gao F, Pourrut X, Barlow KL, Clewley JP, Mwenda JM, Langat DK, Chege GK, McClure HM, Mpoudi-Ngole E, Delaporte E, Peeters M, Shaw GM, Sharp PM, Hahn BH. (2004). New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade. Journal of Virology. 78: 7748-7762.
33. Bick MJ, Carroll JW, Gao G, Goff SP, Rice CM, MacDonald MR. (2003). Expression of the zinc-finger antiviral protein inhibits alphavirus replication. Journal of Virology. 77: 11555-11562.
34. Bieniasz PD, Cullen BR. (2000). Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. Journal of Virology. 74: 9868-9877.
35. Bieniasz PD. (2003). Restriction factors: a defense against retroviral infection. Trends in Microbiology. 11: 286-291.
36. Bieniasz PD. (2004). Intrinsic immunity: a front-line defense against viral attack. Nature Immunology. 5: 1109-1115.
37. Bishop KN, Bock M, Towers G, Stoye JP. (2001). Identification of the regions of Fv1 necessary for murine leukemia virus restriction. Journal of Virology. 75: 5182-5188.
38. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current Biology. 14: 1392-1396.
39. Bishop KN, Holmes RK, Sheehy AM, Malim MH. (2004). APOBEC-mediated editing of viral RNA. Science. 305: 645.
40. Björndal AS, Szekely L, Elgh F. (2003). Ebola virus infection inversely correlates with the overall expression levels of promyelocytic leukaemia (PML) protein in cultured cells. BMC Microbiology. 3: 6.
41. Boeke JD, Stoye JP. (1997). Retrotransposons, endogenous retroviruses, and the evolution of retroelements. In: Coffin JM, Hughes SH, Various HE Eds, Retroviruses. Cold Spring Harbor, Cold Spring Harbor Laboratory Press. pp. 343-436.
42. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. (2004). A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proceedings of the National Academy of Sciences of the USA. 101: 3770-3774.
43. Bonilla WV, Pinschewer DD, Klenerman P, Rousson V, Gaboli M, Pandolfi PP, Zinkernagel RM, Salvato MS, Hengartner H. (2002). Effects of promyelocytic leukemia protein on virus-host balance. Journal of Virology. 76: 3810-3818.
44. Borden KL. (1998). RING fingers and B-boxes: zinc-binding protein-protein interaction domains. Biochemistry and Cell Biology. 76: 351-358.
45. Borden KL. (2000). RING domains: master builders of molecular scaffolds? Journal of Molecular Biology. 295: 1103-1112.
46. Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F. (1995). Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. Journal of Virology. 69: 2058-2067.
47. Borman AM, Quillent C, Charneau P, Kean KM, Clavel F. (1995). A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G->A hypermutation during negative-strand viral DNA synthesis. Virology. 208: 601-609.
48. Bosco DA, Eisenmesser EZ, Pochapsky S, Sandquist WI, Kern D. (2002). Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proceedings of the National Academy of Sciences of the USA. 99: 5247-5252.
49. Both GW. (2002). Identification of a unique family of F-box proteins in atadenoviruses. Virology. 304: 425-433.
50. Bour S, Strebel K. (2003). The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release. Microbes and Infection. 5: 1029-1039.
51. Boutell C, Everett RD. (2003). The herpes simplex virus type 1 HSV-1) regulatory protein ICP0 interacts with and Ubiquitinates p53. Journal of Biological Chemistry. 278: 36596-36602.
52. Bowerman B, Brown PO, Bishop JM, Varmus HE. (1989). A nucleoprotein complex mediates the integration of retroviral DNA. Genes and Development. 3: 469-478.
53. Braaten D, Franke EK, Luban J. (1996). Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. Journal of Virology. 70: 4220-4227.
54. Braaten D, Franke EK, Luban J. (1996). Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. Journal of Virology. 70: 3551-3560.
55. Bransteitter R, Phain P, Scharff MD, Goodman MF. (2003). Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proceedings of the National Academy of Sciences of the USA. 100: 4102-4107.
56. Browning J, Horner JW, Pettoello-Mantovani M, Raker C, Yurasov S, DePinho RA, Goldstein H. (1997). Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proceedings of the National Academy of Sciences of the USA. 94: 14637-14641.
57. Casey JL, Gerin JL. (1995). Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. Journal of Virology. 69: 7593-7600.
58. Cattaneo R. (1994). Biased (A->I) hypermutation of animal RNA virus genomes. Current Opinion in Genetics & Development. 4: 895-900.
59. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L. (2004). The interaction between HIV-1 Gag and APOBEC3G. Journal of Biological Chemistry. 279: 33177-33184.
60. Chan EK, Hamel JC, Buyon JP, Tan EM. (1991). Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. The Journal of Clinical Investigation. 87: 68-76.
61. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. (2003). Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature. 422: 726-730.
62. Chaudhuri J, Khuong C, Alt FW. (2004). Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature. 430: 992-998.
63. Chelbi-Alix MK, Quignon F, Pelicano L, Koken MH, de Thé H. (1998). Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein. Journal of Virology. 72: 1043-1051.
64. Chen SH, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, Deslypere JP, Rosseneu M, Gotto AM, Li VM, Chan L. (1987). Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science. 238: 363-366.
65. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. (2005). Cellular APOBEC3G restricts HIV-1 infection in resting CD4(+) T cells. Nature. 435: 108-114.
66. Coffin JM. (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267: 483-489.
67. Coffin JM. (2004). Evolution of retroviruses: fossils in our DNA. Proceedings of the American Philosophical Society. 148: 264-280.
68. Cohen N, Sharma M, Kentsis A, Perez JM, Strudwick S, Borden KL. (2001). PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA. EMBO Journal. 20: 4547-4559.
69. Consortium TFF. (1997). A candidate gene for familial Mediterranean fever. Nature Genetics. 17: 25-31.
70. Conticello SG, Harris RS, Neuberger MS. (2003). The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Current Biology. 13: 2009-2013.
71. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. (2005). Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Molecular Biology and Evolution. 22: 367-377.
72. Courcoul M, Patience C, Rey F, Blanc D, Harmache A, Sire J, Vigne R, Spire B. (1995). Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. Journal of Virology. 69: 2068-2074.
73. Courgnaud V, Salemi M, Pourrut X, Mpoudi-Ngole E, Abela B, Auzel P, Bibollet-Ruche F, Hahn B, Vandamme AM, Delaporte E, Peeters M. (2002). Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny. Journal of Virology. 76: 8298-8309.
74. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Göttlinger HG, Bieniasz PD. (2002). Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proceedings of the National Academy of Sciences of the USA. 99: 11914-11919.
75. Czarneski J, Rassa JC, Ross SR. (2003). Mouse mammary tumor virus and the immune system. Immunologic Research. 27: 469-480.
76. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. (1991). The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66: 675-684.
77. Declève A, Niwa O, Gelmann E, Kaplan HS. (1975). Replication kinetics of N- and B-tropic murine leukemia viruses on permissive and nonpermissive cells in vitro. Virology. 65: 320-332.
78. Deininger PL, Batzer MA. (1999). Alu repeats and human disease. Molecular Genetics and Metabolism. 67: 183-193.
79. Deininger PL, Batzer MA. (2002). Mammalian retroelements. Genome Research. 12: 1455-1465.
80. Demirov DG, Freed EO. (2004). Retrovirus budding. Virus Research. 106: 87-102.
81. Derse D, Hill SA, Lloyd PA, Chung H, Morse BA (2001). Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. Journal of Virology. 75: 8461-8468.
82. Desbois C, Rousset R, Bantignies F, Jalinot P. (1996). Exclusion of Int-6 from PML nuclear bodies by binding to the HTLV-I Tax oncoprotein. Science. 273: 951-953.
83. Deshaies RJ. (1999). SCF and Cullin/Ring H2-based ubiquitin ligases. Annual Review of Cell and Developmental Biology. 15: 435-467.
84. Desrosiers RC, Lifson JD, Gibbs JS, Czajak SC, Howe AY, Arthur LO, Johnson RP. (1998). Identification of highly attenuated mutants of simian immunodeficiency virus. Journal of Virology. 72: 1431-1437.
85. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF. (2000). Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. Journal of Virology. 74: 8938-8945.
86. Diamonti AJ, Guy PM, Ivanof C, Wong K, Sweeney C, Carraway KL, 3rd. (2002). An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proceedings of the National Academy of Sciences of the USA. 99: 2866-2871.
87. Dickerson SK, Market E, Besmer E, Papavasiliou FN. (2003). AID mediates hypermutation by deaminating single stranded DNA. Journal of Experimental Medicine. 197: 1291-1296.
88. Do H, Vasilescu A, Diop G, Hirtzig T, Heath SC, Coulonges C, Rappaport J, Therwath A, Lathrop M, Matsuda F, Zagury JF. (2005). Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. Journal of Infectious Diseases. 191: 159-163.
89. Dodding MP, Bock M, Yap MW, Stoye JP. (2005). Capsid processing requirements for abrogation of fv1 and ref1 restriction. Journal of Virology. 79: 10571-10577.
90. Doehle BP, Schafer A, Cullen BR. (2005). Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology.
91. Doehle BP, Schafer A, Wiegand HL, Bogerd HP, Cullen BR. (2005). Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. Journal of Virology. 79: 8201-8207.
92. Doi K, Kawana A, Iwamoto A, Yoshikura H, Odawara T. (1997). One base change is sufficient for host range conversion of murine leukemia virus from B to NB tropism. Archives of Virology. 142: 1889-1894.
93. Douaisi M, Dussart S, Courcoul M, Bessou G, Vigne R, Decroly E. (2004). HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochemical and Biophysical Research Communications. 321: 566-573.
94. Duncan SR, Scott S, Duncan CJ. (2005). Reappraisal of the historical selective pressures for the CCR5-Delta32 mutation. Journal of Medical Genetics. 42: 205-208.
95. Durandy A. (2003). Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. European Journal of Immunology. 33: 2069-73.
96. Duran-Troise G, Bassin RH, Rein A, Gerwin BI. (1977). Loss of Fv-1 restriction in Balb/3T3 cells following infection with a single N tropic murine leukemia virus particle. Cell. 10: 479-488.
97. Duran-Troise G, Bassin RH, Wallace BF, Rein A. (1981) Balb/3T3 cells chronically infected with N-tropic murine leukemia virus continue to express Fv-1b restriction. Virology. 112: 795-799.
98. Dussart S, Courcoul M, Bessou G, Douaisi M, Duverger Y, Vigne R, Decroly E. (2004). The Vif protein of human immunodeficiency virus type 1 is posttranslationally modified by ubiquitin. Biochemical and Biophysical Research Communications. 315: 66-72.
99. Dussart S, Douaisi M, Courcoul M, Bessou G, Vigne R, Decroly E. (2005). APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles. Journal of Molecular Biology. 345: 547-558.
100. Dutko JA, Schafer A, Kenny AE, Cullen BF, Curcio MJ. (2005). Inhibition of a Yeast LTR Retrotransposon by Human APOBEC3 Cytidine Deaminases. Current Biology. 15: 661-666.
101. Elvin SJ, Williamson ED, Scott JC, Smith JN, Perez De Lema G, Chilla S, Clapham P, Pfeffer K, Schlondorff D, Luckow B. (2004). Evolutionary genetics: Ambiguous role of CCR5 in Y. pestis infection. Nature. 430: 417.
102. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, Hance AJ, Heidmann T, Schwartz O. (2005). APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature. 433: 430-433.
103. Everett RD, Maul GG. (1994). HSV-1 IE protein Vmw 110 causes redistribution of PML. EMBO Journal. 13: 5062-5069.
104. Everett RD. (2001). DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene. 20: 7266-7273.
105. Fan L, Peden K. (1992). Cell-free transmission of Vif mutants of HIV-1. Virology. 190: 19-29.
106. Fassati A, Goff SP. (1999). Characterization of intracellular reverse transcription complexes of Moloney murine leukemia virus. Journal of Virology. 73: 8919-8925.
107. Fassati A, Goff SP. (2001). Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. Journal of Virology. 75: 3626-3635.
108. Feng F, Davis A, Lake JA, Carr J, Yia W, Burrell C, Li P. (2004). Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif. Journal of Virology. 78: 10574-10581.
109. Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F. (1987). The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science. 237: 888-893.
110. Fitzgibbon JE, Mazar S, Dubin DT. (1993). A new type of G->A hypermutation affecting human immunodeficiency virus. AIDS Research and Human Retroviruses. 9: 833-838.
111. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. (2002). Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. Journal of Virology. 76: 5667-5677.
112. Forshey BM, Shi J, Aiken C. (2005). Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. Journal of Virology. 79: 869-875.
113. Fouchier RA, Simon JH, Jaffe AB, Malim MH. (1996). Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. Journal of Virology. 70: 8263-8269.
114. Franke EK, Yuan HE, Luban J. (1994). Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 372: 359-362.
115. Freemont PS. (2000). RING for destruction? Current Biology. 10: R84-R87.
116. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J. (1992). Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. Journal of Virology. 66: 6489-6495.
117. Gaddis NC, Chertova E, Sheehy AM, Henderson LE, Malim MH. (2003). Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. Journal of Virology. 77: 5810-5820.
118. Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, Beer BE, Marx PA, Gao F, Bibollet-Ruche F, Hahn BH, Malim MH. (2004). Further investigation of simian immunodeficiency virus Vif function in human cells. Journal of Virology. 78: 12041-12046.
119. Galvani AP, Slatkin M. (2003). Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proceedings of the National Academy of Sciences of the USA. 100: 15276-15279.
120. Galvani AP, Novembre J. (2005). The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes and Infection. 7: 302-309.
121. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, Greene BM, Sharp PM, Shaw GM, Hahn BH. (1992). Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. Nature. 358: 495-499.
122. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, Cummins LB, Arthur LO, Peeters M, Shaw GM, Sharp PM, Hahn BH. (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature. 397: 436-441.
123. Gao G, Goff SP. (1999). Somatic cell mutants resistant to retrovirus replication: intracellular blocks during the early stages of infection. Molecular Biology of the Cell. 10: 1705-1717.
124. Gao G, Guo X, Goff SP. (2002). Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein. Science. 297: 1703-1706.
125. Garber ME, Wei P, KewalRamani VN, Mayall TP, Herrmann CH, Rice AP, Littman DR, Jones KA. (1998). The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes and Development. 12: 3512-3527.
126. Gibbs JS, Regier DA, Desrosiers RC. (1994). Construction and in vitro properties of SIVmac mutants with deletions in "nonessential" genes. AIDS Research and Human Retroviruses. 10: 607-616.
127. Gisselbrecht S, Bassin RH, Gerwin BI, Rein A. (1974). Dual susceptibility of A 3T3 mouse cell line to infection by N- and B- tropic murine leukemia virus: apparent lack of expression of the FV-1 gene. International Journal of Cancer. 14: 106-113.
128. Goff SP. (1996). Operating under a Gag order: a block against incoming virus by the Fv1 gene. Cell. 86: 691-693.
129. Gorelick RJ, Nigida SM, Jr., Bess JW, Jr., Arthur LO, Henderson LE, Rein A. (1990). Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. Journal of Virology. 64: 3207-3211.
130. Grewe C, Beck A, Gelderblom HR. (1990). HIV: early virus-cell interactions. Journal of Acquired Immune Deficiency Syndromes. 3: 965-974.
131. Gu Y, Sundquist WI. (2003). Good to CU. Nature. 424: 21-22.
132. Günther S, Sommer G, Plikat U, Iwanska A, Wain-Hobson S, Will H, Meyerhans A. (1997). Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G->A hypermutation. Virology. 235: 104-108.
133. Haché G, Liddament MT, Harris RS. (2005). The retroviral hypermutation specificity of APOBEC317 and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. Journal of Biological Chemistry. 280: 10920-10924.
134. Hahn BH, Shaw GM, De Cock KM, Sharp PM. (2000). AIDS as a zoonosis: scientific and public health implications. Science. 287: 607-614.
135. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. (1984). Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 226: 544-547.
136. Harada JN, Shevchenko A, Pallas DC, Berk AJ. (2002). Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. Journal of Virology. 76: 9194-9206.
137. Harmache A, Russo P, Guiguen F, Vitu C, Vignoni M, Bouyac M, Hieblot C, Pepin M, Vigne R, Suzan M. (1996). Requirement of caprine arthritis encephalitis virus vif gene for in vivo replication. Virology. 224: 246-255.
138. Harris RS, Petersen-Mahrt SK, Neuberger MS. (2002). RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Molecular Cell. 10: 1247-1253.
139. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. (2003). DNA deamination mediates innate immunity to retroviral infection. Cell. 113: 803-809.
140. Harris RS, Sheehy AM, Craig HM, Malim MH, Neuberger MS. (2003). DNA deamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nature Immunology. 4: 641-643.
141. Harris RS, Liddament MT. (2004). Retroviral restriction by APOBEC proteins. Nature Reviews Immunology. 4: 868-877.
142. Hartley JW, Rowe WP, Huebner RJ. (1970). Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. Journal of Virology. 5: 221-225.
143. Hartley JW, Rowe WP. (1975). Clonal cells lines from a feral mouse embryo which lack host-range restrictions for murine leukemia viruses. Virology. 65: 128-134.
144. Hasegawa N, Iwashita T, Asai N, Murakami H, Iwata Y, Isomura T, Goto H, Hayakawa T, Takahashi M. (1996). A RING finger motif regulates transforming activity of the rfp/ret fusion gene. Biochemical and Biophysical Research Communications. 225: 627-631.
145. Hassaine G, Courcoul M, Bessou G, Barthalay Y, Picard C, Olive D, Collette Y, Vigne R, Decroly E. (2001). The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral vif protein. Journal of Biological Chemistry. 276: 16885-16893.
146. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. (2003). Restriction of multiple divergent retroviruses by Lv1 and Refl. EMBO Journal. 22: 385-394.
147. Hatziioannou T, Cowan S, Bieniasz; PD. (2004). Capsid-dependent and -independent postentry restriction of primate lentivirus tropism in rodent cells. Journal of Virology. 78: 1006-1011.
148. Hatziioannou T, Cowan S, Von Schwedler UK, Sundquist WI, Bieniasz PD. (2004). Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. Journal of Virology. 78: 6005-6012.
149. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. (2004). Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. Proceedings of the National Academy of Sciences of the USA. 101: 10774-10779.
150. Hatziioannou T, Perez-Caballero D, Cowan S, Bieniasz PD. (2005). Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. Journal of Virology. 79: 176-183.
151. Hershko A, Ciechanover A. (1998). The ubiquitin system. Annual Review of Biochemistry. 67: 425-479.
152. Himathongkham S, Luciw PA. (1996). Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. Virology. 219: 485-488.
153. Hodges M, Tissot C, Howe K, Grimwade D, Freemont PS. (1998). Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. American Journal of Human Genetics. 63: 297-304.
154. Hofmann W, Schubert D, LaBonte J, Munson L, Gibson S, Scammell J, Ferrigno P, Sodroski J. (1999). Species-specific, postentry barriers to primate immunodeficiency virus infection. Journal of Virology. 73: 10020-10028.
155. Horn EJ, Albor A, Liu Y, El-Hizawi S, Vanderbeek GE, Babcock M, Bowden GT, Hennings H, Lozano G, Weinberg WC, Kulesz-Martin M. (2004). RING protein Trim32 associated with skin carcinogenesis has anti-apoptotic and E3-ubiquitin ligase properties. Carcinogenesis. 25: 157-167.
156. Hsu K, Seharaseyon J, Dong P, Bour S, Marban E. (2004). Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Molecular Cell. 14: 259-267.
157. Hummel S, Schmidt D, Kremeyer B, Herrmann B, Oppermann M. (2005). Detection of the CCR5-Delta32 HIV resistance gene in Bronze Age skeletons. Genes and Immunity. 6: 371-374.
158. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR. (2003). Spread of HTLV-1 between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 299: 1713-1716.
159. Ikeda Y, Ylinen LM, Kahar-Bador M, Towers GJ. (2004). Influence of gag on human immunodeficiency virus type 1 species-specific tropism. Journal of Virology. 78: 11816-11822.
160. Janeway CA, Medzhitov R. (2002). Innate immune recognition. Annual Review of Immunology. 20: 197-216.
161. Janini M, Rogers M, Birx DR, McCutchan FE. (2001). Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells. Journal of Virology. 75: 7973-7986.
162. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. (2002). An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 79: 285-296.
163. Javanbakht H, Diaz-Griffero F, Stremlau M, Si Z, Sodroski J. (2005). The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha. Journal of Biological Chemistry. 280: 26933-26940.
164. Jayan GC, Casey JL. (2002). Increased RNA editing and inhibition of hepatitis delta virus replication by high-level expression of ADAR1 and ADAR2. Journal of Virology. 76: 3819-3827.
165. Jensen K, Shiels C, Freemont PS. (2001). PML protein isoforms and the RBCC/TRIM motif. Oncogene. 20: 7223-7233.
166. Jin MJ, Hui H, Robertson DL, Muller MC, Barré-Sinoussi F, Hirsch VM, Allan JS, Shaw GM, Sharp PM, Hahn BH. (1994). Mosaic genome structure of simian immunodeficiency virus from west African green monkeys. EMBO Journal. 13: 2935-2947.
167. Jin MJ, Rogers J, Phillips-Conroy JE, Allan JS, Desrosiers RC, Shaw GM, Sharp PM, Hahn BH. (1994). Infection of a yellow baboon with simian immunodeficiency virus from African green monkeys: evidence for cross-species transmission in the wild. Journal of Virology. 68: 8454-8460.
168. Jolicoeur P, Baltimore D. (1976). Effect of Fv-1 gene product on proviral DNA formation and integration in cells infected with murine leukemia viruses. Proceedings of the National Academy of Sciences of the USA. 73: 2236-4220.
169. Jolicoeur P. (1979). The Fv-1 gene of the mouse and its control of murine leukemia virus replication. Current Topics in Microbiology and Immunology. 86: 67-122.
170. Jung YT, Kozak CA. (2000). A single amino acid change in the murine leukemia virus capsid gene responsible for the Fv1(nr) phenotype. Journal of Virology. 74: 5385-5387.
171. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. (2003). The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. Journal of Virology. 77: 11398-11407.
172. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. (2004). Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology. 1: 27.
173. Kawamura M, Ishizaki T, Ishimoto A, Shioda T, Kitamura T, Adachi A. (1994). Growth ability of human immunodeficiency virus type 1 auxiliary gene mutants in primary blood macrophage cultures. Journal of General Virology. 75 (Pt 9): 2427-2431.
174. Kazazian HH, Jr., Goodier JL. (2002). LINE drive. retrotransposition and genome instability. Cell. 110: 277-280.
175. Kazazian HH, Jr. (2004). Mobile elements: drivers of genome evolution. Science. 303: 1626-1632.
176. Keckesova Z, Ylinen LM, Towers GJ. (2004). The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities. Proceedings of the National Academy of Sciences of the USA. 101: 10780-10785.
177. Kelly C, Van Driel R, Wilkinson GW. (1995). Disruption of PML-associated nuclear bodies during human cytomegalovirus infection. Journal of General Virology. 76 (Pt 11): 2887-2893.
178. Keppler OT, Yonemoto W, Welte FJ, Patton KS, Iacovides D, Atchison RE, Ngo T, Hirschberg DL, Speck RF, Goldsmith MA. (2001). Susceptibility of rat-derived cells to replication by human immunodeficiency virus type 1. Journal of Virology. 75: 8063-8073.
179. Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou CL, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA. (2002). Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. Journal of Experimental Medicine. 195: 719-736.
180. KewalRamani VN, Coffin JM. (2003). Virology. Weapons of mutational destruction. Science. 301: 923-925.
181. Khan MA, Aberham, C, Kao S, Akari H, Gorelick R, Bour S, Strebel K. (2001). Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. Journal of Virology. 75: 7252-7265.
182. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K. (2005). Viral RNA Is Required for the Association of APOBEC3G with Human Immunodeficiency Virus Type 1 Nucleoprotein Complexes. Journal of Virology. 79: 5870-5874.
183. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. (2005). G->A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. Journal of Virology. 79: 1975-1980.
184. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. (2002). The SOCS box: a tale of destruction and degradation. Trends in Biochemical Sciences. 27: 235-241.
185. Kimura F, Suzu S, Nakamura Y, Nakata Y, Yamada M, Kuwada N, Matsumura. T, Yamashita T, Ikeda T, Sato K, Motoyoshi K. (2003). Cloning and characterization of a novel RING-B-box-coiled-coil protein with apoptotic function. Journal of Biological Chemistry. 278: 25046-25054.
186. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T. (2004). APOBEC3G targets specific virus species. Journal of Virology. 78: 8238-8244.
187. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T. (2005). Ubiquitination of APOBEC3G by an HIV- 1 Vif-cullin5-elonginB-elonginC complex is essential for Vif function. Journal of Biological Chemistry. 280: 18573-18578.
188. Kootstra NA, Münk C, Tonnu N, Landau NR, Verma IM. (2003). Abrogation of postentry restriction of HIV- 1 -based lentiviral vector transduction in simian cells. Proceedings of the National Academy of Sciences of the USA. 100: 1298-1303.
189. Kozak CA. (1985). Analysis of wild-derived mice for Fv- 1 and Fv-2 murine leukemia virus restriction loci: a novel wild mouse Fv-1 allele responsible for lack of host range restriction. Journal of Virology. 55: 281-285.
190. Kozak CA, Chakraborti A. (1996). Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance. Virology. 225: 300-305.
191. Kremer M, Bittner A, Schnierle BS. (2005). Human APOBEC3G incorporation into murine leukemia virus particles. Virology. 337: 175-182.
192. Kristbjörnsdóttir HB, Andrésdóttir V, Svansson V, Torsteinsdóttir S, Matthíasdóttir S, Andrésson OS. (2004). The vif gene of maedivisna virus is essential for infectivity in vivo and in vitro. Virology. 318: 350-359.
193. Lake JA, Carr J, Feng F, Mundy L, Burrell C, Li P. (2003). The role of Vif during HIV-1 infection: interaction with novel host cellular factors. Journal of Clinical Virology. 26: 143-152.
194. Lalonde JP, Lim R, Ingley E, Tilbrook PA, Thompson MJ, McCulloch R, Beaumont JG, Wicking C, Eyre HJ, Sutherland GR, Howe K, Solomon E, Williams JH, Klinken SP. (2004). HLS5, a novel RBCC (ring finger, B box, coiled-coil) family member isolated from a hemopoietic lineage switch, is a candidate tumor suppressor. Journal of Biological Chemistry. 279: 8181-8189.
195. Lander MR, Chattopadhyay SK. (1984). A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ecotropic, amphotropic, xenotropic, and mink cell focus-forming viruses. Journal of Virology. 52: 695-698.
196. Langlois MA, Beale RC, Conticello SG, Neuberger MS. (2005). Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/ G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Research. 33: 1913-1923.
197. Lassaux A, Sitbon M, Battini JL. (2005). Residues in the murine leukemia virus capsid that differentially govern resistance to mouse Fv1 and human Ref1 restrictions. Journal of Virology. 79: 6560-6564.
198. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. (2003). Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300: 1112.
199. Lei M, Liu Y, Samuel CE. (1998). Adenovirus VAI RNA antagonizes the RNA-editing activity of the ADAR adenosine deaminase. Virology. 245: 188-196.
200. Lellek H, Kirsten R, Diehl I, Apostel F, Buck F, Greeve J. (2000). Purification and molecular cloning of a novel essential component of the apolipoprotein B mRNA editing enzyme-complex. Journal of Biological Chemistry. 275: 19848-19856.
201. Li J, Potash MJ, Volsky DJ. (2004). Functional domains of APOBEC3G required for antiviral activity. Journal of Cellular Biochemistry. 92: 560-572.
202. Liao W, Hong SH, Chan BH, Rudolph FB, Clark SC, Chan L. (1999). APOBEC-2, a cardiac- and skeletal muscle-specific member of the cytidine deaminase supergene family. Biochemical and Biophysical Research Communications. 260: 398-404.
203. Liddament MT, Brown WL, Schumacher AJ, Harris RS. (2004). APOBEC3F properties and hypermutation preferences indicate activity against HIV- 1 in vivo. Current Biology. 14: 1385-1391.
204. Lilly F. (1967). Susceptibility to two strains of Friend leukemia virus in mice. Science. 155: 461-462.
205. Lilly F. (1970). Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. Journal of the National Cancer Institute. 45: 163-169.
206. Lindahl T, Wood RD. (1999). Quality control by DNA repair. Science. 286: 1897-1905.
207. Linial ML, Eastman SW. (2003). Particle assembly and genome packaging. Current Topics in Microbiology and Immunology. 277: 89-110.
208. Liu B, Yu X, Luo K, Yu Y, Yu XF. (2004). Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. Journal of Virology. 78: 2072-2081.
209. Liu L, Chen G, Ji X, Gao G. (2004). ZAP is a CRM1-dependent nucleocytoplasmic shuttling protein. Biochemical and Biophysical Research Communications. 321: 517-523.
210. Liu YC. (2004). Ubiquitin ligases and the immune response. Annual Review of Immunology. 22: 81-127.
211. Löchelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, Kim YB, Truyen U, Rösler U, Battenberg M, Saib A, Flory E, Cichutek K, Münk C. (2005). The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proceedings of the National Academy of Sciences of the USA. 102: 7982-7987.
212. Lockridge KM, Himathongkham S, Sawai ET, Chienand M, Sparger EE. (1999). The feline immunodeficiency virus vif gene is required for productive infection of feline peripheral blood mononuclear cells and monocyte-derived macrophages. Virology. 261: 25-30.
213. Longacre A, Storb U. (2000). A novel cytidine deaminase affects antibody diversity. Cell. 102: 541-544.
214. Luban J, Bossolt KL, Franke EK, Kalpana GV, Goff SP. (1993). Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell. 73: 1067-1078.
215. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF. (2004). Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. Journal of Virology, 78: 11841-11852.
216. Ma XY, Sova P, Chao W, Volsky DJ. (1994). Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. Journal of Virology. 68: 1714-1720.
217. Madani N, Kabat D. (1998). An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. Journal of Virology. 72: 10251-10255.
218. Madani N, Millette R, Platt EJ, Marin M, Kozak SL, Bloch DB, Kabat D. (2002). Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. Journal of Virology. 76: 11133-11138.
219. Mager DL, Freeman JD. (2000). Novel mouse type D endogenous proviruses and ETn elements share long terminal repeat and internal sequences. Journal of Virology. 74: 7221-7229.
220. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 424: 99-103.
221. Mangeat B, TuTelli P, Liao S, Trono D. (2004). A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. Journal of Biological Chemistry. 279: 14481-14483.
222. Marchant D, Neil SJ, Aubin K, Schmitz C, McKnight A. (2005). An Envelope-Determined, pH-Independent Endocytic Route of Viral Entry Determines the Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 to Lv2 Restriction. Journal of Virology. 79: 9410-9418.
223. Mariani R, Rutter G, Harris ME, Hope TJ, Kräusslich HG, Landau NR. (2000). A block to human immunodeficiency virus type 1 assembly in murine cells. Journal of Virology. 74: 3859-3870.
224. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. (2003). Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114: 21-31.
225. Marin M, Rose KM, Kozak SL, Kabat D. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Medicine. 5: 1398-1403.
226. Masucci MG. (2004). Epstein-Barr virus oncogenesis and the ubiquitin-proteasome system. Oncogene. 23: 2107-2115.
227. Maul GG, Everett RD. (1994). The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICPO. Journal of General Virology. 75 (Pt 6): 1223-1233.
228. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. (2004). Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes and Development. 18: 2861-2866.
229. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. (2004). Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. Journal of Biological Chemistry. 279: 7792-7798.
230. Mehta A, Kinter MT, Sherman NE, Driscoll DM. (2000). Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Molecular and Cellular Biology. 20: 1846-1854.
231. Meyer M, Gaudieri S, Rhodes DA, Trowsdale J.(2003). Cluster of TRIM genes in the human MHC class I region sharing the B30.2 domain. Tissue Antigens. 61: 63-71.
232. Mi S, Lee X, Li X, Veldman GM, Finnerty H, Racie L, LaVallie E, Tang XY, Edouard P, Howes S, Keith JC, Jr., McCoy JM. (2000). Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis. Nature. 403: 785-789.
233. Michaels FH, Hattori N, Gallo RC, Franchini G. (1993). The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. AIDS Research and Human Retroviruses. 9: 1025-1030.
234. Morita E, Sundquist WI. (2004). Retrovirus budding. Annual Review of Cell and Developmental Biology. 20: 395-425.
235. Mortuza GB, Haire LF, Stevens A, Smerdon SJ, Stoye JP, Taylor IA. (2004). High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature. 431: 481-485.
236. Münk C, Brandt SM, Lucero G, Landau NR. (2002). A dominant block to HIV-1 replication at reverse transcription in simian cells. Proceedings of the National Academy of Sciences of the USA. 99: 13843-13848.
237. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T. (1999). Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. Journal of Biological Chemistry. 274: 18470-18476.
238. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. (2000). Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 102: 553-563.
239. Nakayama EE, Miyoshi H, Nagai Y, Shioda T. (2005). A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection. Journal of Virology. 79: 8870-8877.
240. Navarro F, Bollman B, Chen H, König R, Yu Q, Chiles K, Landau NR. (2005). Complementary function of the two catalytic domains of APOBEC3G. Virology. 333: 374-386.
241. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology. 15: 166-170.
242. Ngui SL, Hallet R, Teo CG. (1999). Natural and iatrogenic variation in hepatitis B virus. Reviews in Medical Virology. 9: 183-209.
243. Nisole S, Lynch C, Stoye JP, Yap MW. (2004). A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proceedings of the National Academy of Sciences of the USA. 101: 13324-13328.
244. Nisole S, Stoye JP, Saib A. (2005). TRIM family proteins: retroviral restriction and antiviral defence. Nature Reviews Microbiology. 3: 799-808.
245. Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, Chayama K. (2005). G to A hypermutation of hepatitis B virus. Hepatology. 41: 626-633.
246. Oberste MS, Gonda MA. (1992). Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes. 6: 95-102.
247. Ochsenbauer C, Wilk T, Bosch V. (1997). Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1. Journal of General Virology. 78 (Pt 3): 627-635.
248. Odaka T, Yamamoto T. (1965). Inheritance of susceptibility to Friend mouse leukemia virus. II. Spleen foci method applied to test the susceptibility of crossbred progeny between a sensitive and a resistant strain. Japanese Journal of Experimental Medicine. 35: 311-314.
249. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K, Honjo T. (2003). Constitutive expression of AID leads to tumorigenesis. Journal of Experimental Medicine. 197: 1173-1181.
250. Orimo A, Yamagishi T, Tominaga N, Yamauchi Y, Hishinuma T, Okada K, Suzuki M, Sato M, Nogi Y, Suzuki H, Inoue S, Yoshimura K, Shimizu Y, Muramatsu M. (2000). Molecular cloning of testis-abundant finger Protein/ Ring finger protein 23 (RNF23), a novel RING-B box-coiled coil-B30.2 protein on the class I region of the human MHC. Biochemical and Biophysical Research Communications. 276: 45-51.
251. Ostertag EM, Kazazian HH, Jr. (2001). Biology of mammalian L1 retrotransposons. Annual Review of Genetics. 35: 501-538.
252. Ott DE. (2002). Potential roles of cellular proteins in HIV-1. Reviews in Medical Virology. 12: 359-374.
253. Owens CM, Yang PC, Göttlinger H, Sodroski J. (2003). Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. Journal of Virology. 77: 726-731.
254. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J. (2004). Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid. Journal of Virology. 78: 5423-5437.
255. Parry G, Estelle M. (2004). Regulation of cullin-based ubiquitin ligases by the Nedd8/RUB ubiquitin-like proteins. Seminars in Cell & Developmental Biology. 15: 221-229.
256. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, Dalla-Favera R. (2001). Hypermutation of multiple photo-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 412: 341-346.
257. Patterson JB, Samuel CE. (1995). Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Molecular and Cellular Biology. 15: 5376-5388.
258. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD. (2005). Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. Journal of Virology. 79: 8969-8978.
259. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J. (2004). TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proceedings of the National Academy of Sciences of the USA. 101: 11827-11832.
260. Pham P, Bransteitter R, Petruska J, Goodman MF. (2003). Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature. 424: 103-107.
261. Pincus T, Hartley JW, Rowe WP. (1971). A major genetic locus affecting resistance to infection with murine leukemia viruses. I. Tissue culture studies of naturally occurring viruses. Journal of Experimental Medicine. 133: 1219-1233.
262. Pintard L, Willems A, Peter M. (2004). Cullin-based ubiquitin ligases: Cu13-BTB complexes join the family. EMBO Journal. 23: 1681-1687.
263. Ponting C, Schultz J, Bork P. (1997). SPRY domains in ryanodine receptors (Ca(2+)-release channels). Trends in Biochemical Sciences. 22: 193-194.
264. Powell LM, Wallis SC, Pease RJ, Edwards YH, Knott TJ, Scott J. (1987). A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell. 50: 831-840.
265. Puvion-Dutilleul F, Chelbi-Alix MK, Koken M, Quignon F, Puvion E, de Thé H. (1995). Adenovirtis infection induces rearrangements in the intranuclear distribution of the nuclear body-associated PML protein. Experimental Cell Research. 218: 9-16.
266. Quaderi NA, Schweiger S, Gaudenz K, Franco B, Rugarli EI, Berger W, Feldman GJ, Volta M, Andolfi G, Gilgenkrantz S, Marion RW, Hennekam RC, Opitz JM, Muenke M, Ropers HH, Ballabio A. (1997). Opitz G/BBB syndrome, a defect of midline development, is due to mutations in a new RING finger gene on Xp22. Nature Genetics. 17: 285-291.
267. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. (2001). Degradation of p53 by adenovirus E4orf6 and EIB55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes and Development. 15: 3104-3117.
268. Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC. (2003). Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nature Immunology. 4: 452-456.
269. Reddy BA, Etkin LD, Freemont PS. (1992). A novel zinc finger coiled-coil domain in a family of nuclear proteins. Trends in Biochemical Sciences. 17: 344-345.
270. Regad T, Chelbi-Alix MK. (2001). Role and fate of PML nuclear bodies in response to interferon and viral infections. Oncogene. 20: 7274-7286.
271. Regad T, Saib A, Lallemand-Breitenbach V, Pandolfi PP, de Thé H, Chelbi-Alix MK. (2001). PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. EMBO Journal. 20: 3495-3505.
272. Rethwilin A. (2003). The replication strategy of foamy viruses. Current Topics in Microbiology and Immunology. 277: 1-26.
273. Reuter S, Kaumanns P, Buschhorn SB, Dittmar MT. (2005). Role of HIV-2 envelope in Lv2-mediated restriction. Virology. 332: 347-358.
274. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, Sanal O, Catalan N, Forveille M, Dufourcq-Labelouse R, Gennery A, Tezcan I, Ersoy F, Kayserili H, Ugazio AG, Brousse N, Muramatsu M, Notarangelo LD, Kinoshita K, Honjo T, Fischer A, Durandy A. (2000). Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 102: 565-575.
275. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A. (2001). The tripartite motif family identifies cell compartments. EMBO Journal. 20: 2140-2151.
276. Reynaud CA, Aoufouchi S, Faili A, Weill JC. (2003). What role for AID: mutator, or assembler of the immunoglobulin mutasome? Nature Immunology. 4: 631-638.
277. Ribeiro AC, Maia e Silva A, Santa-Marta M, Pombo A, Moniz-Pereira J, Goncalves J, Barahona I. (2005). Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. Journal of Virology. 79: 823-833.
278. Risco C, Menendez-Arias L, Copeland TD, Pinto da Silva P, Oroszlan S. (1995). Intracellular transport of the murine leukemia virus during acute infection of NIH 3T3 cells: nuclear import of nucleocapsid protein and integrase. Journal of Cell Science. 108 (Pt 9): 3039-3050.
279. Rock KL, Goldberg AL. (1999). Degradation of cell proteins and the generation of MHC class I-presented peptides. Annual Review of Immunology. 17: 739-779.
280. Rosa-Calatrava M, Puvion-Dutilleul F, Lutz P, Dreyer D, de Thé H, Chatton B, Kedinger C. (2003). Adenovirus protein IX sequesters host-cell promyelocytic leukaemia protein and contributes to efficient viral proliferation. EMBO Reports. 4: 969-975.
281. Rösler C, Kock J, Malim MH, Blum HE, von Weizsäcker F. (2004). Comment on "Inhibition of hepatitis B virus replication by APOBEC3G". Science. 305: 1403.
282. Rösler C, Kock J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsäcker F. (2005). APOBEC-mediated interference with hepadnavirus production. Hepatology. 42: 301-309.
283. Russell RA, Wiegand HL, Moore MD, Schafer A, McClure MO, Cullen BR. (2005). Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. Journal of Virology. 79: 8724-8731.
284. Sakai H, Shibata R, Sakuragi J, Sakuragi S, Kawamura M, Adachi A. (1993). Cell-dependent requirement of human immuno-deficiency virus type 1 Vif protein for maturation of virus particles. Journal of Virology. 67: 1663-1666.
285. Sakai K, Ma XY, Gordienko I, Volsky DJ. (1991). Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV- 1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity. Journal of Virology. 65: 5765-5773.
286. Samuel CE. (2001). Antiviral actions of interferons. Clinical Microbiology Reviews. 14: 778-809.
287. Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J. (2005). HIV-1 Vif Can Directly Inhibit Apolipoprotein B mRNA-editing Enzyme Catalytic Polypeptide- like 3G-mediated Cytidine Deamination by Using a Single Amino Acid Interaction and Without Protein Degradation. Journal of Biological Chemistry. 280: 8765-8775.
288. Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, Imada K, Tanaka Y, Uchiyama T. (2005). APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology. 2: 32.
289. Saurin AJ, Borden KL, Boddy MN, Freemont PS. (1996). Does this have a familiar RING? Trends in Biochemical Sciences. 21: 208-214.
290. Sawyer SL, Emerman M, Malik HS. (2004). Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biology. 2: E275.
291. Sawyer SL, Wu LI, Emerman M, Malik HS. (2005). Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proceedings of the National Academy of Sciences of the USA. 102: 2832-2837.
292. Sayah DM, Luban J. (2004). Selection for loss of Ref1 activity in human cells releases human immunodeficiency virus type 1 from cyclophilin A dependence during infection. Journal of Virology. 78: 12066-12070.
293. Sayah DM, Sokolskaja E, Berthoux L, Luban J. (2004). Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 430: 569-573.
294. Schäfer A, Bogerd HP, Cullen BR. (2004). Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology. 328: 163-168.
295. Scheffner M, Whitaker NJ. (2003). Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Seminars in Cancer Biology. 13: 59-67.
296. Schmitz C, Marchant D, Neil SJ, Aubin K, Reuter S, Dittmar MT, McKnight A. (2004). Lv2, a novel postentry restriction, is mediated by both capsid and envelope. Journal of Virology. 78: 2006-2016.
297. Schröfelbauer B, Chen D, Landau NR. (2004). A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proceedings of the National Academy of Sciences of the USA. 101: 3927-3932.
298. Schumacher AJ, Nissley DV, Harris RS. (2005). APOBEC3G hypermutates genomic DNA and inhibits Tyl retrotransposition in yeast. Proceedings of the National Academy of Sciences of the USA. 102: 9854-9859.
299. Schwartz O, Marechal V, Friguet B, Arenzana-Seisdedos F, Heard JM. (1998). Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1. Journal of Virology. 72: 3845-3850.
300. Sebastian S, Luban J. (2005). TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology. 2: 40.
301. Sen GC. (2001). Viruses and interferons. Annual Review of Microbiology. 55: 255-281.
302. Shacklett BL, Luciw PA. (1994). Analysis of the vif gene of feline immunodeficiency virus. Virology. 204: 860-867.
303. Sharp PM, Bailes E, Robertson DL, Gao F, Hahn BH. (1999). Origins and evolution of AIDS viruses. The Biological Bulletin. 196: 338-342.
304. Sheehy AM, Gaddis NC, Choi JD, Malim MH. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418: 646-650.
305. Sheehy AM, Gaddis NC, Malim MH. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV- 1 Vif. Nature Medicine. 5: 1404-1407.
306. Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, Adachi A. (1991). Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. Journal of Virology. 65: 3514-3520.
307. Shibata R, Sakai H, Kawamura M, Tokunaga K, Adachi A. (1995). Early replication block of human immunodeficiency virus type 1 in monkey cells. Journal of General Virology. 76: 2723-2730.
308. Shindo K, Takaori-Kondo A, Kobayashi M, Abudu A, Fukunaga K, Uchiyama T. (2003). The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. Journal of Biological Chemistry. 278: 44412-44416.
309. Simon JH, Southerling TE, Peterson JC, Meyer BE, Malim MH. (1995). Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. Journal of Virology. 69: 4166-4172.
310. Simon JH, Malim MH. (1996). The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. Journal of Virology. 70: 5297-5305.
311. Simon JH, Gaddis NC, Fouchier RA, Malim MH. (1998). Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature Medicine. 4: 1397-1400.
312. Simon JH, Miller DL, Fouchier RA, Soares MA, Peden KW, Malim MH. (1998). The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO Journal. 17: 1259-1267.
313. Simon JH, Sheehy AM, Carpenter EA, Fouchier RA, Malim MH. (1999). Mutational analysis of the human immunodeficiency virus type 1 Vif protein. Journal of Virology. 73: 2675-2681.
314. Skurat AV, Dietrich AD, Zhai L, Roach PJ. (2002). GNIP, a novel protein that binds and activates glycogenin, the self-glucosylating initiator of glycogen biosynthesis. Journal of Biological Chemistry. 277: 19331-19338.
315. Slack FJ, Ruvkun G. (1998). A novel repeat domain that is often associated with RING finger and B-box motifs. Trends in Biochemical Sciences. 23: 474-475.
316. Smith HC, Gott JM, Hanson MR. (1997). A guide to RNA editing. RNA. 3: 1105-1123.
317. Smith HC, Bottaro A, Sowden MP, Wedekind JE. (2004). Activation induced deaminase: the importance of being specific. Trends in Genetics. 20: 224-227.
318. Sohail A, Klapacz J, Samaranayake M, Ullah A, Bhagwat AS. (2003). Human activation-induced cytidine deaminase causes transcription-dependent, strand-biased C to U deaminations. Nucleic Acids Research. 31: 2990-2994.
319. Sokolskaja E, Sayah DM, Luban J. (2004). Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. Journal of Virology. 78: 12800-12808.
320. Song B, Javanbakht H, Perron M, Park do H, Stremlau. M, Sodroski J. (2005). Retrovirus Restriction by TRIM5{alpha} Variants from Old World and New World Primates. Journal of Virology. 79: 3930-3937.
321. Souquiere S, Bibollet-Ruche F, Robertson DL, Makuwa M, Apetrei C, Onanga R, Kornfeld C, Plantier JC, Gao F, Abernethy K, White LJ, Karesh W, Telfer P, Wickings EJ, Mauclere P, Marx PA, Barré-Sinoussi F, Hahn BH, Muller-Trutwin MC, Simon F. (2001). Wild Mandrillus sphinx are carriers of two types of lentivirus. Journal of Virology. 75: 7086-7096.
322. Sova P, Volsky DJ. (1993). Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. Journal of Virology. 67: 6322-6326.
323. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. (1998). How cells respond to interferons. Annual Review of Biochemistry. 67: 227-264.
324. Steeves R, Lilly F. (1977). Interactions between host and viral genomes in mouse leukemia. Annual Review of Genetics. 11: 277-296.
325. Stevens A, Bock M, Ellis S, LeTissier P, Bishop KN, Yap MW, Taylor W, Stoye JP. (2004). Retroviral capsid determinants of Fv1 NB and NR tropism. Journal of Virology. 78: 9592-9598.
326. Stopak K, de Noronha C, Yonemoto W, Greene WC. (2003). HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell. 12: 591-601.
327. Stoye JP, Coffin JM. (2000). A provirus put to work. Nature. 403: 715, 717.
328. Stoye JP. (2002). An intracellular block to primate lentivirus replication. Proceedings of the National Academy of Sciences of the USA. 99: 11549-11551.
329. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA. (1987). The HIV 'A' (sor) gene product is essential for virus infectivity. Nature. 328: 728-730.
330. Strebel K. (2004). HIV-1 Vpu: putting a channel to the TASK. Molecular Cell. 14: 150-152.
331. Strebel K. (2005). APOBEC3G & HTLV-1: inhibition without deamination. Retrovirology. 2: 37.
332. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. (2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 427: 848-853.
333. Stremlau M, Perron M, Welikala S, Sodroski J. (2005). Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. Journal of Virology. 79: 3139-3145.
334. Suspène R, Sommer P, Henry M, Ferris S, Guetard D, Pochet S, Chester A, Navaratnam N, Wain-Hobson S, Vartanian JP. (2004). APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Research. 32: 2421-2429.
335. Suspène R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. (2005). Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proceedings of the National Academy of Sciences of the USA. 102: 8321-8326.
336. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK. (2004). Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. Journal of Biological Chemistry. 279: 35822-35828.
337. Swindle CS, Zou N, Van Tine BA, Shaw GM, Engler JA, Chow LT. (1999). Human papillomavirus DNA replication compartments in a transient DNA replication system. Journal of Virology. 73: 1001-1009.
338. Takahashi M, Cooper GM. (1987). ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Molecular and Cellular Biology. 7: 1378-1385.
339. Takehisa J, Harada Y, Ndembi N, Mboudjeka I, Taniguchi Y, Ngansop C, Kuate S, Zekeng L, Ibuki K, Shimada T, Bikandou B, Yamaguchi-Kabata Y, Miura T, Ikeda M, Ichimura H, Kaptue L, Hayami M. (2001). Natural infection of wild-born mandrills (Mandrillus sphinx) with two different types of simian imunodeficiency virus. AIDS Research and Human Retroviruses. 17: 1143-1154.
340. Takemura T, Hayami M. (2004). Phylogenetic analysis of SIV derived from mandrill and drill. Frontiers in Biosciences. 9: 513-520.
341. Takeuchi H, Kao S, Miyagi E, Khan MA, Buckler-White A, Plishka R, Strebel K. (2005). Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G. Journal of Biological Chemistry. 280: 375-382.
342. Taylor WR, Stoye JP. (2004). Consensus structural models for the amino terminal domain of the retrovirus restriction gene Fv1 and the murine leukaemia virus capsid proteins. BMC Structural Biology. 4: 1.
343. Telesnitsky A, Goff SP. (1997). Reverse transcriptase and the generation of retroviral DNA. In: Coffin JM, Hughes SH, Varmus HE Eds, Retroviruses. Cold Spring Harbor, Cold Spring Harbor Laboratry Press. pp 121-160.
344. Teng B, Burant CF, Davidson NO. (1993). Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science. 260: 1816-1819.
345. Tennant RW, Otten JA, Brown A, Yang WK, Kennel SJ. (1979). Characterization of Fv-1 host range strains of murine retroviruses by titration and p30 protein characteristics. Virology. 99: 349-357.
346. Thali M, Bukovsky A, Kondo E, Rosenwirth B, Walsh CT, Sodroski J, Göttlinger HG. (1994). Functional association of cyclophilin A with HIV-1 virions. Nature. 372: 363-365.
347. Tomonaga K, Norimine J, Shin YS, Fukasawa M, Miyazawa T, Adachi A, Toyosaki T, Kawaguchi Y, Kai C, Mikami T. (1992). Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. Journal of Virology. 66: 6181-6185.
348. Towers G, Bock M, Martin S, Takeuchi Y, Stoye JP, Danos O. (2000). A conserved mechanism of retrovirus restriction in mammals. Proceedings of the National Academy of Sciences of the USA. 97: 12295-12299.
349. Towers G, Collins M, Takeuchi Y. (2002). Abrogation of Ref1 retrovirus restriction in human cells. Journal of Virology. 76: 2548-2550.
350. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. (2003). Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Medicine. 9: 1138-1143.
351. Towers GJ. (2005). Control of viral infectivity by tripartite motif proteins. Human Gene Therapy. 16: 1125-1132.
352. Trockenbacher A, Suckow V, Foerster J, Winter J, Krauss S, Ropers HH, Schneider R, Schweiger S. (2001). MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nature Genetics. 29: 287-294.
353. Turelli P, Doucas V, Craig E, Mangeat B, Klages N, Evans R, Kalpana G, Trono D. (2001). Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Molecular Cell. 7: 1245-1254.
354. Turelli P, Jost S, Mangeat B, Trono D. (2004). Response to Comment on "Inhibition of Hepatitis B Virus Replication by APOBEC3G". Science. 305: 1403.
355. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. (2004). Inhibition of hepatitis B virus replication by APOBEC3G. Science. 303: 1829.
356. Turelli P, Vianin S, Trono D. (2004). The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. Journal of Biological Chemistry. 279: 43371-43373.
357. Urano T, Saito T, Tsukui T, Fujita M, Hosoi T, Muramatsu M, Ouchi Y, Inoue S. (2002). Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 417: 871-875.
358. van der Wal FJ, Kikkert M, Wiertz E. (2002). The HCMV gene products US2 and US11 target MHC class I molecules for degradation in the cytosol. Current Topics in Microbiology and Imunology. 269: 37-55.
359. Vandeputte DA, Meije CB, van Dartel M, Leenstra S, H IJ-K, Das PK, Troost D, Bosch DA, Baas F, Hulsebos TJ. (2001). GOA, a novel gene encoding a ring finger B-box coiled-coil protein, is overexpressed in astrocytoma. Biochemical and Biophysical Research Communications. 286: 574-579.
360. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. (1991). Selection, recombination, and G->A hypermutation of human immunodeficiency virus type 1 genomes. Journal of Virology. 65: 1779-1788.
361. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. (1994). G- >A hypermutation of the human immunodeficiency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proceedings of the National Academy of Sciences of the USA. 91: 3092-3096.
362. Vartanian JP, Henry M, Wain-Hobson S. (2002). Sustained G->A hypermutation during reverse transcription of an entire human immunodeficiency virus type 1 strain Vau group O genome. Journal of General Virology. 83: 801-805.
363. Varthakavi V, Smith RM, Bour SP, Strebel K, Spearman P. (2003). Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production. Proceedings of the National Academy of Sciences of the USA. 100: 15154-15159.
364. Verschoor EJ, Fagrouch Z, Bontjer I, Niphuis H, Heeney JL. (2004). A novel simian immunodeficiency virus isolated from a Schmidt's guenon (Cercopithecus ascanius schmidti). Journal of General Virology. 85: 21-24.
365. Vichi A, Payne DM, Pacheco-Rodriguez G, Moss J, Vaughan M. (2005). E3 ubiquitin ligase activity of the trifunctional ARDI (ADP-ribosylation factor domain protein 1). Proceedings of the National Academy of Sciences of the USA. 102: 1945-1950.
366. Villesen P, Aagaard L, Wiuf C, Pedersen FS. (2004). Identification of endogenous retroviral reading frames in the human genome. Retrovirology. 1: 32.
367. Vincent SR, Kwasnicka DA, Fretier P. (2000). A novel RING finger-B box-coiled-coil protein, GERP. Biochemical and Biophysical Research Communications. 279: 482-486.
368. von Schwedler U, Song J, Aiken C, Trono D. (1993). Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. Journal of Virology. 67: 4945-4955.
369. Walsh CP, Chaillet JR, Bestor TH. (1998). Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nature Genetics. 20: 116-117.
370. Wang CL, Harper RA, Wabl M. (2004). Genome-wide somatic hypermutation. Proceedings of the National Academy of Sciences of the USA. 101: 7352-7356.
371. Wang H, Sakurai A, Khamsri B, Uchiyama T, Gu H, Adachi A, Fujita M. (2005). Unique characteristics of HIV-1 Vif expression. Microbes and Infection. 7: 385-390.
372. Wang Y, Li Y, Qi X, Yuan W, Ai J, Zhu C, Cao L, Yang H, Liu F, Wu X, Liu M. (2004). TRIM45, a novel human RBCC/TRIM protein, inhibits transcriptional activities of E1K-1 and AP-1. Biochemical and Biophysical Research Communications. 323: 9-16.
373. Watanabe N, Okochi E, Mochizuki M, Sugimura T, Ushijima T. (2001). The presence of single nucleotide instability in human breast cancer cell lines. Cancer Research. 61: 7739-7742.
374. Wedekind JE, Dance GS, Sowden MP, Smith HC. (2003). Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends in Genetics. 19: 207-216.
375. Wichroski MJ, Ichiyama K, Rana TM. (2005). Analysis of HIV-1 Viral Infectivity Factor-mediated Proteasome-dependent Depletion of APOBEC3G: Correlating Function and Subcellular Localization. Journal of Biological Chemistry. 280: 8387-8396.
376. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. (2004). A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO Journal. 23: 2451-2458.
377. Wiegers K, Kräusslich HG. (2002). Differential dependence of the infectivity of HIV-1 group O isolates on the cellular protein cyclophilin A. Virology. 294: 289-295.
378. Wieland S, Thimme R, Purcell RH, Chisari FV. (2004). Genomic analysis of the host response to hepatitis B virus infection. Proceedings of the National Academy of Sciences of the USA. 101: 6669-6674.
379. Wills JW, Craven RC. (1991). Form, function, and use of retroviral gag proteins. AIDS. 5: 639-654.
380. Wong SK, Lazinski DW. (2002). Replicating hepatitis delta virus RNA is edited in the nucleus by the small form of ADAR1 Proceedings of the National Academy of Sciences of the USA. 99: 15118-15123.
381. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK. (2004). A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proceedings of the National Academy of Sciences of the USA. 101: 5652-5657.
382. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, Taylor S, Taylor JM, Innerarity TL. (1995). Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proceedings of the National Academy of Sciences of the USA. 92: 8483-8487.
383. Yan KP, Dolle P, Mark M, Lerouge T, Wendling O, Chambon P, Losson R. (2004). Molecular cloning, genomic structure, and expression analysis of the mouse transcriptional intermediary factor 1 gamma gene. Gene. 334: 3-13.
384. Yang S, Sun Y, Zhang H. (2001). The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. Journal of Biological Chemistry. 276: 4889-4893.
385. Yang WK, Kiggans, JO, Yang DM, Ou CY, Tennant RW, Brown A, Bassin RH. (1980). Synthesis and circularization of N- and B- tropic retroviral DNA in Fv-1 permissive and restrictive mouse cells. Proceedings of the National Academy of Sciences of the USA. 77: 2994-2998.
386. Yang X, Goncalves J, Gabuzda D. (1996). Phosphorylation of Vif and its role in HIV-1 replication. Journal of Biological Chemistry. 271: 10121-10129.
387. Yang X, Gabuzda D. (1998). Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. Journal of Biological Chemistry. 273: 29879-29887.
388. Yap MW, Stoye JP. (2003). Intracellular localisation of Fv1 Virology. 307: 76-89.
389. Yap MW, Nisole S, Lynch C, Stoye JP. (2004). Trim5alpha protein restricts both HIV-1 and murine leukemia virus. Proceedings of the National Academy of Sciences of the USA. 101: 10786-10791.
390. Yap MW, Nisole S, Stoye JP. (2005). A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Current Biology. 15: 73-78.
391. Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ. (2005). Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. Journal of Virology. 79: 11580-11587.
392. Yoo S, Myszka DG, Yeh C, McMurray M, Hill CP, Sundquist WI. (1997). Molecular recognition in the HIV-1 capsid/cyclophilin A complex. Journal of Molecular Biology. 269: 780-795.
393. Yoshikawa K, Okazaki IM, Eto T, Kinoshita K, Muramatsu M, Nagaoka H, Honjo T. (2002). AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science. 296: 2033-2036.
394. Yu Q, Chen D, König R, Mariani R, Unutmaz D, Landau NR. (2004). APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. Journal of Biological Chemistry. 279: 53379-53386.
395. Yu Q, König R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. (2004). Single-strand specificity of APOBEC3G accounts for minus-strand dearnination of the HIV genome. Nature Structural and Molecular Biology. 11: 435-442.
396. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. (2003). Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 302:1056-1060.
397. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. (2004). Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes and Development. 18: 2867-2872.
398. Yuan B, Li X, Goff SP. (1999). Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO Journal. 18: 4700-4710.
399. Yuan B, Fassati A, Yueh A, Goff SP. (2002). Characterization of Moloney murine leukemia virus p12 mutants blocked during early events of infection. Journal of Virology. 76: 10801-10810.
400. Yueh A, Goff SP. (2003). Phosphorylated serine residues and an arginine-rich domain of the moloney murine leukemia virus p12 protein are required for early events of viral infection. Journal of Virology. 77: 1820-1829.
401. Zennou V, Perez-Caballero D, Göttlinger H, Bieniasz PD. (2004). APOBEC3G incorporation into human immunodeficiency virus type 1 particles. Journal of Virology. 78: 12058-12061.
402. Zhang H, Pomerantz RJ, Dornadula, G, Sun Y. (2000). Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. Journal of Virology. 74: 8252-8261.
403. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424: 94-98.
404. Zhang J, Webb DM. (2004). Rapid evolution of primate antiviral enzyme APOBEC3G. Human Molecular Genetics. 13: 1785-1791.
405. Zheng YH, Yu HF, Peterlin BM. (2003). Human p32 protein relieves a post-transcriptional block to HIV replication in murine cells. Nature Cell Biology. 5: 611-618.
406. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. (2004). Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. Journal of Virology. 78: 6073-6076.
407. Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H. (2002). How acute promyelocytic leukaemia revived arsenic. Nature Reviews Cancer. 2: 705-713.